AYBINTIO

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug AYBINTIO contains one active pharmaceutical ingredient (API):

1	Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB
	Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
	Read more about Bevacizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AYBINTIO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FG01	Bevacizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1826153, 1826164
ES	Centro de información online de medicamentos de la AEMPS	1201454001
FR	Base de données publique des médicaments	65303582
GB	Medicines & Healthcare Products Regulatory Agency	390142, 390157
LT	Valstybinė vaistų kontrolės tarnyba	1091011, 1091012
PL	Rejestru Produktów Leczniczych	100439365